Blog
RSS FeedPosted by Michael Wonder on 18 Nov 2019
Improving transparency in decision models: current issues and potential solutions
23 October 2019 - Decision-analytic models have become an essential tool used to inform health technology assessments. ...
Posted by Michael Wonder on 18 Nov 2019
NICE, in confidence: an assessment of redaction to obscure confidential information in single technology appraisals by the National Institute for Health and Care Excellence
17 November 2019 - Health technology assessment aims to provide a transparent framework within which normative judgements can be applied for ...
Posted by Michael Wonder on 12 Oct 2019
Canada's decision to make public more clinical trial data puts pressure on FDA
11 October 2019 - Last March, Canada's department of health changed the way it handles the huge amount of data ...
Posted by Michael Wonder on 01 Oct 2019
Why transparency in drug pricing is more complicated than it seems
1 October 2019 - Transparency has become a prominent topic in debates about health care, particularly when it comes to ...
Posted by Michael Wonder on 30 Sep 2019
1 October 2019 price disclosure confirmed prices
30 September 2019 - Confirmed 1 October 2019 prices resulting from the 2019 October Cycle of Price Disclosure have now been ...
Posted by Michael Wonder on 09 Sep 2019
Achieving appropriate model transparency: challenges and potential solutions for making value‑based decisions in the United States
5 September 2019 - Transparency in decision modeling remains a topic of rigorous debate among healthcare stakeholders, given tensions between the ...
Posted by Michael Wonder on 05 Sep 2019
What is the value of market-wide health care price transparency?
5 September 2019 - A primary driver of high spending in the US health care system, relative to other countries, ...
Posted by Michael Wonder on 04 Sep 2019
Capital Rx to inject transparency in prescription drug prices
4 September 2019 - In recent years, the pharmacy benefits management industry's pricing practices have been under intense scrutiny by ...
Posted by Michael Wonder on 25 Aug 2019
Time for FDA to release complete responses letters? Debate reignites.
23 August 2019 - The idea of the US FDA releasing complete response letters resurfaced this week as Sarepta Therapeutics ...
Posted by Michael Wonder on 21 Aug 2019
Appealing court ruling, Trump administration renews fight to require drug prices in TV ads
21 August 2019 - The Trump administration isn’t giving up the fight to require drug makers include their sticker prices ...
Posted by Michael Wonder on 19 Aug 2019
Extension to feedback for public consultation - standardised redactions of PBAC Public Summary Documents
19 August 2019 - On 30 July 2019, the Department of Health held an information forum to provide industry, consumers and ...
Posted by Michael Wonder on 18 Aug 2019
Lack of transparency hampers cancer drug debate
19 August 2019 - The current debate raging over cancer drug funding is emotional, and the different agenda of lobby ...
Posted by Michael Wonder on 08 Aug 2019
Insurers snooping in our health records
9 August 2019 - Life insurers have trawled through the medical records of 150,000 Australians in an attempt to deny ...
Posted by Michael Wonder on 02 Aug 2019
Public consultation – standardised redactions of Public Summary Documents
2 August 2019 - On 30 July 2019, the Department of Health held an information forum to provide industry, consumers ...
Posted by Michael Wonder on 01 Aug 2019
Proposal to enhance the transparency of CADTH’s review reports and recommendations
31 July 2019 - CADTH is committed to increasing the transparency of its health technology assessment processes. ...